Application Detail
Description of Medical Service
Etranacogene dezaparvovec is a gene therapy designed to introduce a copy of the Factor IX (FIX) gene to address the lack of functional FIX protein expression in a haemophila B patient. The therapy is delivered by infusion into the bloodstream.Description of Medical Condition
Haemophilia is a congenital lifelong bleeding disorder caused by deficiencies in coagulation factors as a result of mutations in clotting factor genes. Haemophilia B is less common than Haemophilia A, accounting for approximately 15% of total cases, and the majority of people affected are male due to the associated coagulation factor being found on the X chromosome.Reason for Application
Referral from the National Blood AuthorityMedical Service Type
Therapeutic technologyPrevious Application Number/s
Not ApplicableAssociated Documentation
Application Form
Application Form (PDF 1133 KB)Application Form (Word 185 KB)
Consultation Survey
Consultation Survey (PDF 658 KB)Consultation Survey (Word 27 KB)
PASC Consultation
Consultation closed
MSAC Consultation
MSAC consultation input must be received by no later than Friday, 14 June 2024 for it to be considered by MSAC at its August 2024 meeting.
For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process
PICO Confirmation
PICO Confirmation (PDF 1523 KB)PICO Confirmation (Word 328 KB)